Your search returned 6 results.

Results
	1.	CI-1033, an irreversible pan-erbB receptor inhibitor and its potential application for the treatment of breast cancer. [electronic resource] by Allen, Lee F Eiseman, Irene A Fry, David W Lenehan, Peter F Producer: 20031212 In: Seminars in oncology vol. 30 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	2.	Potential benefits of the irreversible pan-erbB inhibitor, CI-1033, in the treatment of breast cancer. [electronic resource] by Allen, Lee F Lenehan, Peter F Eiseman, Irene A Elliott, William L Fry, David W Producer: 20020814 In: Seminars in oncology vol. 29 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	3.	A phase I clinical and pharmacokinetic study of oral CI-1033 in combination with docetaxel in patients with advanced solid tumors. [electronic resource] by Garland, Linda L Hidalgo, Manuel Mendelson, David S Ryan, David P Arun, Banu K Lovalvo, Jennifer L Eiseman, Irene A Olson, Stephen C Lenehan, Peter F Eder, Joseph P Producer: 20070126 In: Clinical cancer research : an official journal of the American Association for Cancer Research vol. 12 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	4.	Administration of CI-1033, an irreversible pan-erbB tyrosine kinase inhibitor, is feasible on a 7-day on, 7-day off schedule: a phase I pharmacokinetic and food effect study. [electronic resource] by Calvo, Emiliano Tolcher, Anthony W Hammond, Lisa A Patnaik, Amita de Bono, Johan S Eiseman, Irene A Olson, Stephen C Lenehan, Peter F McCreery, Heather Lorusso, Patricia Rowinsky, Eric K Producer: 20050503 In: Clinical cancer research : an official journal of the American Association for Cancer Research vol. 10 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	5.	Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advanced non small-cell lung cancer. [electronic resource] by Jänne, Pasi A von Pawel, Joachim Cohen, Roger B Crino, Lucio Butts, Charles A Olson, Steven S Eiseman, Irene A Chiappori, Alberto A Yeap, Beow Y Lenehan, Peter F Dasse, Kathy Sheeran, Meredith Bonomi, Philip D Producer: 20070911 In: Journal of clinical oncology : official journal of the American Society of Clinical Oncology vol. 25 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	6.	Increased bioavailability of intravenous versus oral CI-1033, a pan erbB tyrosine kinase inhibitor: results of a phase I pharmacokinetic study. [electronic resource] by Simon, George R Garrett, Christopher R Olson, Stephen C Langevin, Michael Eiseman, Irene A Mahany, John J Williams, Charles C Lush, Richard Daud, Adil Munster, Pamela Chiappori, Alberto Fishman, Mayer Bepler, Gerold Lenehan, Peter F Sullivan, Daniel M Producer: 20071214 In: Clinical cancer research : an official journal of the American Association for Cancer Research vol. 12 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)